Reducing the Burden of Hepatocellular Carcinoma Among Migrant Populations: Improving prevention and outcomes through disease modeling

项目摘要 肝细胞癌是美国癌症死亡率增长最快的原因。肝细胞癌是 可以预防，而且它对患有未被识别的无症状慢性病毒性肝炎的移民影响不成比例 (CVH)。该项目的长期目标是减少流动人口中可预防的肝癌的发生。 人口。这项建议的总体目标是估计慢性病毒性肝炎(CVH)和 肝细胞癌在移民中的患病率，以检测与高风险相关的关键标识 负担组，并描述这些组的共病和结果。实现这一目标的目的是 目标是减少流动人口中可预防的肝癌的发生。这项研究将有助于 这是通过生成患者、从业者和决策者所需的流行病学数据来实现的 以便更容易地确定哪些移民群体将从战略筛选和 监视系统。 中心假设是移民中的肝癌和CVH的风险和结果可以通过以下方式来估计 人口统计数据。这将通过追求两个具体目标进行测试：1)建立CVH和肝细胞癌的患病率 在流动人口中；以及2)确定流动人口中CVH和肝细胞癌的共病和结局 人口。在第一个目标下，一个经过验证的CVH和肝癌疾病模型将与流动人口配对 统计数据，以确定不同移徙人口的风险概况，包括年龄组和原籍国。 在第二个目标下，将利用现有的具有追溯性的全人口健康数据集来确定 在不同的流动人口中常见的伴随疾病和结果。拟议的研究是 创新，因为它侧重于确定特定移民群体特有的关键特征，并 建立相关的CVH和肝细胞癌风险概况。如果实现，预计结果将是显著的。 因为它们将有助于解决目前在疾病负担方面的知识差距和 不同的移民人口，允许进行风险分层和适当修改以进行影响筛选 政策和实践。

Project Summary Hepatocellular carcinoma (HCC) is the fastest growing cause of cancer mortality in the United States. HCC is preventable, and it disproportionately affects migrants with unrecognized asymptomatic Chronic Viral Hepatitis (CVH). The long-term goal of this project is to reduce the occurrence of preventable liver cancer in migrant populations. The overall objective of this proposal is to estimate the Chronic Viral Hepatitis (CVH) and Hepatocellular Carcinoma (HCC) prevalence among migrants, to detect key identifiers associated with high- burden groups, and to describe the comorbidities and outcomes of those groups. The purpose of achieving this goal is to reduce the occurrence of preventable liver cancer in migrant populations. This study will contribute to this through the generation of the epidemiological data required for patients, practitioners, and policymakers alike to more readily identify the migrant groups that would benefit most from strategic screening and surveillance. The central hypothesis is that HCC and CVH risk and outcomes among migrants can be estimated by demographics. This will be tested by pursuing two specific aims: 1) Establish prevalence of CVH and HCC among migrant populations; and 2) Identify CVH and HCC comorbidities and outcomes within the migrant population. Under the first aim, a proven CVH and HCC disease model will be paired with migrant population statistics to establish the risk profiles for distinct migrant populations, including age group and country-of-origin. Under the second aim, an existing retrospective, population-wide health dataset will be utilized to identify common concomitant disease and outcomes among distinct migrant populations. The proposed research is innovative because it focuses on identifying key characteristics unique to specific migrant populations and establishing the associated CVH and HCC risk profiles. If achieved, the results are expected to be significant because they will contribute to resolving the current knowledge gaps in the disease burden and disparities of distinct migrant populations, allowing for risk stratifying and appropriate modifications to impact screening policy and practice.